“FDA in the 21st Century: The Challenges of Regulating Drugs and New Technologies,” edited by Holly Fernandez Lynch and I. Glenn Cohen ’03 (Columbia). Stemming from a 2013 conference at HLS, the book features essays covering major developments that have changed how the FDA regulates; how the agency encourages transparency; First Amendment issues; access to drugs; and evolving issues in drug-safety communication. These issues, the editors write, lie “at the heart of our health and health care.”
On March 29, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School celebrated its first decade and kicked off the next with a conference that focused on the future of health law and policy.
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Coalition to Transform Advanced Care (C-TAC) today announced a new collaboration, The Project on Advanced Care and Health Policy.
In a visit to Harvard Law School on Jan. 20, former U.S. Food and Drug Administration commissioner Dr. Margaret A. Hamburg HMS ’83 reflected on her six-year tenure at the agency and shared her thoughts about the future of public health regulation.
With a nod to its historic past and a look ahead to its future, Harvard Law School has formally launched the Campaign for the Third Century, which seeks to raise $305 million in support of students and faculty, clinical education, new and innovative research, and the continued enhancement of the Law School campus.
Karaoke with five HLS professors. A fashion shopping spree with Professor I. Glenn Cohen ’03. A classic movie night with Dean Martha Minow. These were just a few of the unique experiences auctioned off at the 21st annual Public Interest Auction on April 9th.
For the growing number of empiricists at HLS, there’s nothing quite so satisfying—or unimpeachable—as resolving a thorny, often contentious, legal or policy question through rigorous analysis of cold, hard data.
As far back as Aristotle, people have been touting the benefits of group decision-making. Yet, as Professor Cass R. Sunstein ’78 and and Reid Hastie note in their new book, history suggests that groups are often unwise or downright foolish.
Smart phones and other mobile devices have the potential to transform healthcare, improving medical outcomes, reducing errors, and broadening access to healthcare. The Food and Drug Administration must continue to have jurisdiction over these “mobile health” or “mHealth” innovations to address emerging risks, according to I. Glenn Cohen, Nathan G. Cortez, and Aaron S. Kesselheim, […]
Cass Sunstein opened the 2014 Behavioral Economics, Law, and Health Policy Conference with a keynote address called “Choosing Not to Choose.” His talk set the tone for the two-day conference organized by The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, which drew nearly 200 lawyers, public health professionals, economists, and health policy analysts to the campus from May 2-3.